0001209191-23-043301.txt : 20230725
0001209191-23-043301.hdr.sgml : 20230725
20230725162202
ACCESSION NUMBER: 0001209191-23-043301
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230721
FILED AS OF DATE: 20230725
DATE AS OF CHANGE: 20230725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bonaccorso Joe
CENTRAL INDEX KEY: 0001741973
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38529
FILM NUMBER: 231108799
MAIL ADDRESS:
STREET 1: C/O VERRICA PHARMACEUTICALS INC.
STREET 2: 10 NORTH HIGH STREET, SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001660334
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463137900
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
BUSINESS PHONE: 484-453-3300
MAIL ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-21
0
0001660334
Verrica Pharmaceuticals Inc.
VRCA
0001741973
Bonaccorso Joe
C/O VERRICA PHARMACEUTICALS INC.
44 WEST GAY STREET, SUITE 400
WEST CHESTER
PA
19380
0
1
0
0
Chief Commercial Officer
0
Common Stock
2023-07-21
4
A
0
100000
0.00
A
101000
D
Common Stock
2023-07-24
4
S
0
38262
4.83
D
62738
D
Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs
vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the
remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.
Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-07-25